Castle Rock Wealth Management LLC grew its position in Bristol-Myers Squibb Co (NYSE:BMY) by 22.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,870 shares of the biopharmaceutical company’s stock after purchasing an additional 2,028 shares during the quarter. Castle Rock Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $488,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of BMY. FMR LLC grew its position in shares of Bristol-Myers Squibb by 313.9% in the 1st quarter. FMR LLC now owns 40,851,887 shares of the biopharmaceutical company’s stock worth $1,949,043,000 after buying an additional 30,981,844 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Bristol-Myers Squibb by 75.7% in the 2nd quarter. Janus Henderson Group PLC now owns 16,156,559 shares of the biopharmaceutical company’s stock valued at $732,691,000 after purchasing an additional 6,960,047 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Bristol-Myers Squibb by 1.1% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,251,891 shares of the biopharmaceutical company’s stock valued at $328,873,000 after purchasing an additional 78,260 shares in the last quarter. Nordea Investment Management AB raised its position in shares of Bristol-Myers Squibb by 380.2% in the 1st quarter. Nordea Investment Management AB now owns 6,252,847 shares of the biopharmaceutical company’s stock valued at $298,324,000 after purchasing an additional 4,950,748 shares in the last quarter. Finally, California Public Employees Retirement System raised its position in shares of Bristol-Myers Squibb by 14.3% in the 1st quarter. California Public Employees Retirement System now owns 5,118,016 shares of the biopharmaceutical company’s stock valued at $244,181,000 after purchasing an additional 642,267 shares in the last quarter. 80.27% of the stock is currently owned by institutional investors.
In other Bristol-Myers Squibb news, Director Robert J. Bertolini purchased 11,000 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was purchased at an average cost of $44.72 per share, for a total transaction of $491,920.00. Following the acquisition, the director now owns 11,397 shares in the company, valued at approximately $509,673.84. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.13% of the company’s stock.
BMY has been the topic of a number of recent analyst reports. Argus lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 target price on the stock. in a research report on Monday, May 20th. UBS Group dropped their price target on Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a research report on Thursday, June 13th. Atlantic Securities upgraded Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price objective for the company in a research note on Wednesday, August 14th. Bank of America upped their price objective on Bristol-Myers Squibb from $46.00 to $49.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 3rd. Finally, Goldman Sachs Group began coverage on Bristol-Myers Squibb in a research note on Tuesday, May 28th. They set a “buy” rating and a $54.00 price objective for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $55.74.
BMY stock traded up $0.10 during midday trading on Friday, reaching $49.71. 775,356 shares of the company’s stock traded hands, compared to its average volume of 9,503,818. The company has a 50-day simple moving average of $46.87 and a two-hundred day simple moving average of $47.14. The company has a market cap of $81.44 billion, a price-to-earnings ratio of 12.49, a PEG ratio of 2.39 and a beta of 0.70. Bristol-Myers Squibb Co has a 1-year low of $42.48 and a 1-year high of $63.69. The company has a quick ratio of 3.75, a current ratio of 3.88 and a debt-to-equity ratio of 1.51.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a return on equity of 47.63% and a net margin of 26.14%. The company had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.10 billion. During the same period in the prior year, the company earned $1.01 EPS. Bristol-Myers Squibb’s revenue was up 10.0% compared to the same quarter last year. Equities research analysts forecast that Bristol-Myers Squibb Co will post 4.28 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be issued a dividend of $0.41 per share. The ex-dividend date of this dividend is Thursday, October 3rd. This represents a $1.64 dividend on an annualized basis and a yield of 3.30%. Bristol-Myers Squibb’s payout ratio is currently 41.21%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Recommended Story: Street Name
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.